Progenics Pharmaceuticals, Inc.
One World Trade Center, 47th Floor, Suite J, New York, NY 10007
Phone: (646) 975-2500Website: https://www.progenics.com/Careers: www.progenics.com/about-us/careers
- FDA Approves Azedra (iobenguane I 131) for Rare Adrenal Tumors
30 July 2018
- Progenics Pharmaceuticals Announces Three-Month Extension of PDUFA Date for Azedra (iobenguane I 131)
22 March 2018
- Progenics Pharmaceuticals Announces FDA Acceptance of New Drug Application for Azedra (iobenguane I 131) in Pheochromocytoma and Paraganglioma
29 December 2017
- Progenics Pharmaceuticals Completes Submission of NDA for Azedra (iobenguane I 131) in Pheochromocytoma and Paraganglioma
2 November 2017
Drugs Associated with Progenics Pharmaceuticals, Inc.
Progenics Pharmaceuticals, Inc. manufactures, markets and/or distributes 1 drug in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
Generic name: iobenguane I 131
Drug class: therapeutic radiopharmaceuticals
|For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective).|